CY1120210T1 - Παραλλαγες αντισωματων anti-tfpi με διαφορικη δεσμευση στην περιοχη ρη για βελτιωμενη φαρμακοκινητικη - Google Patents

Παραλλαγες αντισωματων anti-tfpi με διαφορικη δεσμευση στην περιοχη ρη για βελτιωμενη φαρμακοκινητικη

Info

Publication number
CY1120210T1
CY1120210T1 CY20181100096T CY181100096T CY1120210T1 CY 1120210 T1 CY1120210 T1 CY 1120210T1 CY 20181100096 T CY20181100096 T CY 20181100096T CY 181100096 T CY181100096 T CY 181100096T CY 1120210 T1 CY1120210 T1 CY 1120210T1
Authority
CY
Cyprus
Prior art keywords
parallels
tfpi
lower affinity
area
antibody
Prior art date
Application number
CY20181100096T
Other languages
English (en)
Inventor
Zhuozhi Wang
John E. Murphy
Ruth WINTER
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CY1120210T1 publication Critical patent/CY1120210T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Αποκαλύπτονται αντισώματα που δεσμεύονται και αναστέλλουν την αντιπηκτική λειτουργία του TFPI και έχουν χαμηλότερη συγγένεια για TFPI σε pΗ 6,0 από ότι σε pΗ 7,4. Η χαμηλότερη συγγένεια σε pΗ 6 βελτιώνει την ημιζωή στην κυκλοφορία (Τ 1/2) λόγω μειωμένης κάθαρσης που μεσολαβείται από στόχο, μια διαδικασία με την οποία ένα σύμπλοκο αντισώματος/αντιγόνου υφίσταται ενδοκύττωση και μεταφορά στο λυσόσωμα, όπου αποικοδομούνται και τα δύο συστατικά. Η χαμηλότερη συγγένεια σε pΗ 6,0 έχει ως αποτέλεσμα την διάσπαση του συμπλόκου, πριν από την στόχευση στο λυσόσωμα και επιτρέπει την επανακυκλοφορία του αντισώματος. Ειδικές τροποποιήσεις στην δέσμευση αντισώματος με υποκατάσταση του καταλοίπου ιστιδίνης αποκαλύπτονται μαζί με μεθόδους χρήσης.
CY20181100096T 2013-03-15 2018-01-24 Παραλλαγες αντισωματων anti-tfpi με διαφορικη δεσμευση στην περιοχη ρη για βελτιωμενη φαρμακοκινητικη CY1120210T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798261P 2013-03-15 2013-03-15
PCT/US2014/029048 WO2014144577A1 (en) 2013-03-15 2014-03-14 Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics

Publications (1)

Publication Number Publication Date
CY1120210T1 true CY1120210T1 (el) 2018-12-12

Family

ID=50928243

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100096T CY1120210T1 (el) 2013-03-15 2018-01-24 Παραλλαγες αντισωματων anti-tfpi με διαφορικη δεσμευση στην περιοχη ρη για βελτιωμενη φαρμακοκινητικη

Country Status (18)

Country Link
US (3) US20160009818A1 (el)
EP (1) EP2970497B1 (el)
JP (4) JP6454678B2 (el)
CN (2) CN113788897A (el)
CA (1) CA2906128A1 (el)
CY (1) CY1120210T1 (el)
DK (1) DK2970497T3 (el)
ES (1) ES2657304T3 (el)
HK (1) HK1218128A1 (el)
HR (1) HRP20180078T1 (el)
HU (1) HUE037907T2 (el)
LT (1) LT2970497T (el)
NO (1) NO3022387T3 (el)
PL (1) PL2970497T3 (el)
PT (1) PT2970497T (el)
RS (1) RS56814B1 (el)
SI (1) SI2970497T1 (el)
WO (1) WO2014144577A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3101298A1 (en) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
BR112013021526B1 (pt) 2011-02-25 2021-09-21 Chugai Seiyaku Kabushiki Kaisha Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
BR112014013081A2 (pt) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha veículo contendo fármaco em célula para formação de um complexo imune
CA2882272C (en) 2012-08-24 2023-08-29 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc region variant
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
JP6227191B1 (ja) 2014-12-19 2017-11-08 中外製薬株式会社 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
BR112017018328A2 (pt) * 2015-02-25 2018-07-10 Mogam Institute For Biomedical Research anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo
NZ739871A (en) 2015-08-19 2022-05-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
JP7289913B2 (ja) 2018-10-11 2023-06-12 ファイザー・インク Ｔｆｐｉアンタゴニストのための投薬レジメン

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2708559T3 (en) * 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP2379600B2 (en) 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
CA3101298A1 (en) * 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
SA111320266B1 (ar) * 2010-03-11 2015-06-21 رينات نيوروساينس كوربوريشن أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني
EA034214B1 (ru) 2011-04-01 2020-01-17 Байер Хелфкеа Ллк Выделенное моноклональное антитело или его антигенсвязывающий фрагмент, который связывается с эпитопом ингибитора пути тканевого фактора человека, содержащая его фармацевтическая композиция, способ применения этой композиции и кодирующая антитело молекула нуклеиновой кислоты
BR112014024373A2 (pt) * 2012-03-30 2017-08-08 Bayer Healthcare Llc anticorpos regulados por protease
CA2881679C (en) * 2012-08-13 2021-01-26 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
CN104704416B (zh) * 2012-08-15 2018-07-31 卢西德股份有限公司 用于对组织进行成像的系统和方法
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Also Published As

Publication number Publication date
JP6697064B2 (ja) 2020-05-20
CN113788897A (zh) 2021-12-14
WO2014144577A1 (en) 2014-09-18
LT2970497T (lt) 2018-03-12
CA2906128A1 (en) 2014-09-18
US20160009818A1 (en) 2016-01-14
US20180282430A1 (en) 2018-10-04
JP2019069973A (ja) 2019-05-09
JP2021107436A (ja) 2021-07-29
JP2020079250A (ja) 2020-05-28
DK2970497T3 (da) 2018-01-29
EP2970497B1 (en) 2017-10-25
JP6454678B2 (ja) 2019-01-16
EP2970497A1 (en) 2016-01-20
CN105452298B (zh) 2021-08-31
CN105452298A (zh) 2016-03-30
US20140275493A1 (en) 2014-09-18
NO3022387T3 (el) 2018-08-25
HUE037907T2 (hu) 2018-09-28
ES2657304T3 (es) 2018-03-02
PL2970497T3 (pl) 2018-05-30
RS56814B1 (sr) 2018-04-30
JP2016514683A (ja) 2016-05-23
PT2970497T (pt) 2018-01-30
HRP20180078T1 (hr) 2018-03-09
US9556280B2 (en) 2017-01-31
SI2970497T1 (en) 2018-04-30
HK1218128A1 (zh) 2017-02-03

Similar Documents

Publication Publication Date Title
CY1120210T1 (el) Παραλλαγες αντισωματων anti-tfpi με διαφορικη δεσμευση στην περιοχη ρη για βελτιωμενη φαρμακοκινητικη
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
PH12018501079A1 (en) Ctla4 binders
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
PH12018501080A1 (en) Pd1 and/or lag3 binders
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112017006203A2 (pt) anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune.
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
TN2014000120A1 (en) Cd27l antigen binding proteins
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
MY186708A (en) Constructs targeting afp peptide/mhc complexes and uses thereof
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
NZ703581A (en) Anti-cd70 antibody drug conjugates
PH12015501284A1 (en) Bcma antigen binding proteins
BR112015023418A2 (pt) conjugado de anticorpo e fármaco, anticorpo ou fragmento de ligação de antígeno, seus processos de produção, seus usos, ácido nucleico, vetor, e célula hospedeira
EA202091166A1 (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
MX2016003744A (es) Anticuerpos tem8 y su uso.
ECSP12012272A (es) Proteínas que se unen al tnf-?
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
MX2016001145A (es) Proteina de fusion terapeutica.
EA201792058A1 (ru) Виротерапия комбинацией антител
TR201819828T4 (tr) Anti-fosfolipaz d4 antikoru.
GB201202631D0 (en) Method of measuring interaction between molecules